Stay updated with breaking news from Optimizing Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Marcia Brose, MD, examines data from the COSMIC-311 study, emphasizing the importance of promptly initiating second-line therapy for patients who have progressed on first-line treatments.
Daniel Bowles, MD, discusses the toxicity profiles and adverse reactions associated with frontline and second-line treatments for differentiated thyroid cancer (DTC).
Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.
Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.
Francis Worden, MD, analyzes the outcomes of the SELECT and DECISION Trials, focusing on progression-free survival, and provides recommendations for their application in clinical practice.